Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/10854/3808

Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals
Massanella, Marta; Ouchi, Dan; Marfil, Sílvia; Llibre, Josep M.; Puertas, M.C.; Buzon, Maria J.; Richman, Douglas D.; Orna, Elisa; Stevenson, Mario; Gatell, J.M.; Domingo, Pere; Negredo, Eugenia; Martinez Picado, Francisco Javier; Clotet, Bonaventura; Blanco, Julià
Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades
Abstract Background HIV-1 infection increases plasma levels of inflammatory markers. Combination antiretroviral therapy (cART) does not restore inflammatory markers to normal levels. Since intensification of cART with raltegravir reduced CD8 T-cell activation in the Discor-Ral and IntegRal studies, we have evaluated the effect of raltegravir intensification on several soluble inflammation markers in these studies. Methods Longitudinal plasma samples (0–48 weeks) from the IntegRal (n = 67, 22 control and 45 intensified individuals) and the Discor-Ral studies (44 individuals with CD4 T-cell counts<350 cells/µl, 14 control and 30 intensified) were assayed for 25 markers. Mann-Whitney, Wilcoxon, Spearman test and linear mixed models were used for analysis. Results At baseline, different inflammatory markers were strongly associated with HCV co-infection, lower CD4 counts and with cART regimens (being higher in PI-treated individuals), but poorly correlated with detection of markers of residual viral replication. Although raltegravir intensification reduced inflammation in individuals with lower CD4 T-cell counts, no effect of intensification was observed on plasma markers of inflammation in a global analysis. An association was found, however, between reductions in immune activation and plasma levels of the coagulation marker D-dimer, which exclusively decreased in intensified patients on protease inhibitor (PI)-based cART regimens (P = 0.040). Conclusions The inflammatory profile in treated HIV-infected individuals showed a complex association with HCV co-infection, the levels of CD4 T cells and the cART regimen. Raltegravir intensification specifically reduced D-dimer levels in PI-treated patients, highlighting the link between cART composition and residual viral replication; however, raltegravir had little effect on other inflammatory markers.
2014
Sida -- Tractament
Aquest document està subjecte a una llicència Creative Commons:
15 p.
Artículo
Public Library of Science
         

Documentos con el texto completo de este documento

Ficheros Tamaño Formato
artconlli_a2014 ... fferent_plasma_markers.pdf 927.9 KB PDF

Mostrar el registro completo del ítem

Documentos relacionados

Otros documentos del mismo autor/a

Kawana-Tachikawa, A.; Llibre, Josep M.; Bravo, Isabel; Escrig, R.; Mothe, B.; Puig, Jordi; Puertas, M.C.; Martinez Picado, Francisco Javier; Blanco, Julià; Manzardo, C.; Miró, J.M.; Iwamoto, A.; Pozniak, A.L.; Gatell, J.M.; Clotet, Bonaventura; Brander, Christian
Massanella, Marta; Gómez-Mora, Elisabet; Carrillo, Jorge; Curriu, Marta; Ouchi, Dan; Puig, Jordi; Negredo, Eugenia; Cabrera, Cecilia; Clotet, Bonaventura; Blanco, Julià
Echeverria, Patricia; Domingo, Pere; Llibre, Josep M.; Gutierrez, Mar; Mateo, Gracia; Puig, Jordi; Bonjoch, Anna; Pérez Alvarez, Núria; Sirera, Guillem; Clotet, Bonaventura; Negredo, Eugenia
Molinos-Albert, Luis M.; Carrillo, Jorge; Curriu, Marta; Rodríguez de la Concepción, Maria L.; Marfil, Sílvia; García, Elisabet; Clotet, Bonaventura; Blanco, Julià
Carrillo, Jorge; Molinos-Albert, Luis M.; Rodríguez de la Concepción, Maria L.; Marfil, Sílvia; García, Elisabet; Derking, Ronald; Sanders, Rogier W.; Clotet, Bonaventura; Blanco, Julià